Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Monte Rosa Therapeutics (GLUE) is back in focus after updated Phase 1/2 data for MRT-2359 in metastatic castration-resistant prostate cancer, together with a planned Phase 2 move and a sizeable public offering to fund its pipeline.
See our latest analysis for Monte Rosa Therapeutics.
At a share price of $17.80, Monte Rosa’s recent news around MRT-2359 and the planned public offering comes after a 16.26% year to date share price return and a very large 1 year total shareholder return of 178.56%. This suggests recent momentum has cooled slightly compared to the strong gains already booked.
If this kind of biotech catalyst has caught your attention, it could be a good moment to widen your watchlist with our 32 healthcare AI stocks sourced directly from the Simply Wall St screener.
With Monte Rosa’s share price already reflecting a very large 1 year return and trading close to some intrinsic estimates, the key question now is whether today’s level is an entry point or if markets are already pricing in future growth.
Monte Rosa Therapeutics currently trades on a P/E of 67.3x, based on its recent close of $17.80. This places it at a premium compared to both peers and the wider US biotech industry.
The P/E ratio compares the company’s share price to its earnings per share, so a higher P/E usually means the market is paying more today for each dollar of current earnings. For a clinical stage biotech that has only recently become profitable, this often reflects expectations around future cash flows, pipeline progress and potential commercialization rather than mature, steady earnings.
What stands out here is how far that 67.3x multiple sits above reference points. It is higher than the peer group average of 42.7x and well above the US Biotechs industry average of 21.2x. This suggests the market is pricing in materially stronger outcomes than are implied for the sector overall. Our model based fair P/E of 11.3x is also significantly lower than the current level, pointing to a gap that could narrow over time if sentiment or expectations shift.
Explore the SWS fair ratio for Monte Rosa Therapeutics
Result: Price-to-Earnings of 67.3x (OVERVALUED)
However, you still need to weigh clinical and regulatory uncertainty around MRT-2359, as well as the annual revenue and net income growth rates moving in the wrong direction.
